H. Lundbeck (LUN) Q3 2026 earnings summary
Event summary combining transcript, slides, and related documents.
Q3 2026 earnings summary
11 Nov, 2026Executive summary
9M 2026 revenue reached DKK 20,191m, up 13% CER (9% in DKK); underlying growth was 11% CER after excluding a DKK 470m Partner Markets inventory build.
Vyepti and Rexulti led growth; strategic brands rose 16% CER to DKK 15,951m.
Adjusted EBITDA increased 19% CER to DKK 7,026m; net debt/EBITDA fell to 0.7x from 1.3x a year earlier.
FY 2026 revenue growth guidance rose to 11%-12% CER and adjusted EBITDA growth to 15%-19% CER.
Commercial momentum, pipeline progress and a reshaped operating model support the 2027 Scale phase.
Financial highlights
9M EBIT rose 13% in DKK to DKK 5,409m; net profit increased 30% to DKK 4,073m.
Adjusted net profit was DKK 5,369m and adjusted EPS was DKK 5.42, up 25%; reported EPS was DKK 4.11, up 30%.
Q3 revenue was DKK 6,603m, up 7% CER; adjusted EBITDA was DKK 2,261m, up 17% CER.
9M operating cash flow was DKK 5,010m; free cash flow was DKK 4,557m versus DKK 4,151m.
Outlook and guidance
FY 2026 growth guidance increased to 11%-12% for revenue and 15%-19% for adjusted EBITDA, both at CER, from prior ranges of 7%-9% and 8%-14%.
Adjusted gross margin guidance is 86%-87%; R&D costs DKK 5.6bn-DKK 5.7bn; D&A ~DKK 1.9bn; net debt DKK 4.0bn-DKK 5.0bn.
Q4 growth is expected to moderate as the DKK 470m Partner Markets inventory build does not recur; Trintellix generic entry and increased Rexulti competition also weigh on the outlook.
Bexicaserin DEEP OCEAN results were expected in Q4 2026, DEEP SEA in Q1 2027; amlenetug pivotal results are expected in Q3 2027.
Mid-term targets remain mid-single-digit revenue CAGR for 2023-2027 and adjusted EBITDA margin above 30% in 2027, excluding business development activity.
Latest events from H. Lundbeck
- Upgraded guidance and late-stage catalysts support the 2027–2029 scale phase.LUN
Jefferies Global Healthcare Conference - Vyepti-led growth and stronger earnings lifted FY 2026 guidance as leverage fell.LUN
Q3 2026 - Strategic-brand growth and pipeline investment support 2026 growth amid generic headwinds.LUN
Q4 2025 - Strong growth, innovation, and capital discipline drive long-term value and shareholder returns.LUN
Investor update - H1 2026 saw 16% CER revenue growth, strong brand and pipeline momentum, and guidance maintained.LUN
Q2 2026 - H1 2026 revenue up 16% CER, strong cash flow, and robust growth from Vyepti and Rexulti.LUN
Q2 2026 - Bocunebart showed strong efficacy and safety in migraine prevention, advancing to Phase III.LUN
Study update - Q1 2026 saw 21% CER revenue growth, margin expansion, and upgraded full-year guidance.LUN
Q1 2026 - Transformative year with late-stage pipeline advances and disciplined capital allocation.LUN
43rd Annual J.P. Morgan Healthcare Conference